A new study released today by MD Anderson Cancer Center in Texas shows that a family of microRNAs (miR-200) blocks cancer progression by cutting off the tumor’s ability to build new blood vessels. These findings highlight the potential of biomarkers for identifying patients who might benefit from treatment. Dr. Anil Sood says “safety studies will need to be completed before clinical development can begin.”
Read more here
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
